Biotech Making Insulin to sell at 70% Less Than Current Prices; Crop Treatment That Increases Yields By Up To 40%, Rapid COVID-19 Test And More
Biologx Proprietary Technology Rapidly Produces Insulin, at 70% Less Than Current Prices to the Patient
Biologx has devised unique processes for the production of Insulin that enable them to make high-quality insulin in the US at lower cost. Attractive Investment that can save lives.
- 35–40% higher product yield compared to competitors
- 5 times faster production time
- 3 times fewer production steps
- 75% less overhead expenses
Biologx has filed with the SEC to qualify their Reg A+. Make a reservation now to lock in the initial share price.
Reserve now — Minimum reservation $300
Huge market. Unique, Patented Tech. Proven. Excellent Timing
Proprietary technology increases crop yields up to 40% while producing healthier, stronger, and more productive organic crops.
- The Organic food market has scale — $45 Bill per annul revenues, growing rapidly.
- ONIT Grow™ has shown that it can generate farmers $15 for every $1 spent on it.
- Years in the making, now is a good time to invest in this company that promises to scale up in a big way. Invest in the worldwide expansion of ONIT Grow™ now to lock in a favorable valuation while you still can!
For Accredited Investors only — $10k minimum
Building compact and portable test devices to detect COVID-19
Edoceo is raising $20M with their Reg A+ offering to fast-track the development of its SARS-CoV-2 Virus Test for use in Doctor’s offices, Clinics, and Airports.
- Results in under 30 minutes
- Affordable
- Accurate method that greatly reduces false positive and negative results
- COVID-19 test based on RNA amplification
Anyone can invest — Minimum Investment $580
Invest in companies developing virus tests, treatments, and vaccines
By investing you enable us to invest and lend capital to select companies that are developing virus tests, medicines, vaccines and related technologies that protect the public.
The Manhattan Street Fund will work with Manhattan Street Capital by lending and investing to provide capital to enable successful Reg A+ public offerings and (IPOs). We will make distributions of profit quarterly and we intend to provide monthly redemptions with reasonable limits.
Anyone can make a reservation in our planned Reg A+*. Reserve $200 or more to lock in the initial Unit price.
For accredited investors — The Convertible Note conversion cost per Unit is $1.40 and your investment will convert into Units in the Reg A+* at the value of $4.00 (at the pre-money valuation for the Reg A+* of $50 mill). *Subject to SEC Qualification. Conversion is optional.
CalTier realty specializes in multi-family investments across the united states.
Multi-Family Real Estate Investment Fund Building a diversified multi-family real estate portfolio.
Anyone can invest — Minimum investment $500
Rod Turner
CEO Manhattan Street Capital
Rod Turner is a seasoned serial entrepreneur. CEO of Manhattan Street Capital, founder and General Partner of the Manhattan Street Fund, he helps CEOs raise capital via IPOs, Regulation A+ for Mid-Stage companies. Manhattan Street Capital, 858 366 2585
Check the Offering Circular on any offering before investing for important details.
We are paid to list these offerings
Please read our important investor warnings here
DISCLOSURES: Manhattanstreetcapital.com is a website owned and operated by Manhattan Street Capital (“MSC”), a DBA of FundAthena, Inc. MSC is paid fees by the companies that make investment and reservation offerings on this website. Be aware that payment of these fees may put MSC in a conflict of interest with the investor. See the MSC fee schedule here. By accessing this website or any page thereof, you agree to be bound by the Terms of Use and Privacy Policy, as amended from time to time and in effect at the most recent time you access this website or any page thereof. Nothing on this website shall constitute an offer to sell, or a solicitation of an offer to subscribe for or buy, any securities to any person in any jurisdiction to whom or in which such offer or solicitation is unlawful. Consequently, any featured, front page or prominent placement of a listed company on this site is not deemed to be a recommendation and may be based on various algorithms or selections that drive traffic to such listed company. MSC does not effect securities transactions, give investment advice or recommend any securities as it is not registered as a broker-dealer, Reg CF funding portal or investment adviser with the U.S. Securities and Exchange Commission or the securities regulatory commission, agency or body of any state of the United States or any non-U.S. jurisdiction. As such, MSC is not acting in a fiduciary capacity with respect to any user of the MSC services, and MSC disclaims any broker-client or advisor-client relationship with respect to any party using those services. Listed companies are actively seeking to raise early stage capital pursuant to Rule 506(b) or Rule 506(c) of Regulation D (“Regulation D”) under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or pursuant to Regulation A (sometimes referred to as “Regulation A+”) under the Securities Act (“Regulation A”). A listed company’s offerings are being made by, and all the information included on this website relating to a listed company and its securities has been provided by and is the responsibility of, such listed company. A listed company’s offerings on this website, if made pursuant to Rule 506(b) or Rule 506(c) of Regulation D, generally are available only to “accredited investors” as defined in Regulation D. Accredited investors are able to identify listed companies in which they may have an interest after a certification process for Rule 506(b) offerings, while Rule 506(c) offerings are available for the general public to view. Offerings made pursuant to Regulation A are also generally available for the general public to view. Investing in securities, particularly in securities issued by start-up companies, involves substantial risk, and investors should be able to bear the loss of their entire investment. All investors should make their own determination of whether or not to make any investment based on their own independent evaluation and analysis. See our Investor Risks and Education Guide. MSC does not verify or assure that information provided by any listed company offering its securities is accurate or complete or that the valuation of such securities is appropriate. The content (Blogs, FAQs, News) posted on MSC may contain incorrect information, always get professional advice. Neither MSC nor any of its directors, officers, employees, representatives, affiliates or agents shall have any liability whatsoever arising from any error or incompleteness of fact or opinion in, or lack of care in the preparation of, any of the materials posted on this website. MSC does not provide legal, accounting or tax advice. Any representation or implication to the contrary is expressly disclaimed.
You can learn more about investing in Regulation D and Regulation A offerings from the SEC or FINRA.
© Copyright 2019 Manhattan Street Capital, Inc. All rights reserved. Patents pending. Copyright and Trademarks owned by Manhattan Street Capital.
